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Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help
to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression.
A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational
Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations
such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction
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and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac
phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each
with different fibrosis subtypes and a different composition of various cells and proteins — resulting in a very complex pathophysiology.
As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of
fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation,
but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the
mechanisms and the caveats and proposes a roadmap for future research.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Fibrosis is a fundamental process observed in cardiac remodelling
and considered to be a key contributor to heart failure and its
progression. Importantly, the presence and extent of myocardial
fibrosis has also prognostic implications, as it causes contractile
dysfunction and arrhythmias in structural heart disease of vari-
ous aetiologies.1–6 Fibrosis is a direct and indirect target in the
treatment of heart failure, either by established drug therapies
(e.g. angiotensin-converting enzyme inhibitors or mineralocorti-
coid receptor antagonists) or specific anti-fibrotic drugs (e.g. pir-
fenidone). However, its resilience to therapy requires additional
major efforts to control (and ideally prevent or reverse) fibrotic
remodelling, being identified as a major contributor to heart failure
progression.1–6
While fibrosis is a widely used term, the exact definition is
less precisely defined. Fibrosis in the broadest sense is defined as
excessive accumulation of extracellular matrix (ECM). In simpli-
fied terms, fibrosis can be divided into (i) ‘reparative fibrosis’ and
(ii) ‘reactive fibrosis’. The development of an organized scar after
myocardial infarction (MI) can be best described as reparative or
replacement fibrosis, which is necessary to mechanically stabilize
the evolving (necrotic) tissue defect. In contrast, the fine interstitial
‘reactive fibrosis’ encountered in non-ischaemic cardiomyopathies
or in the surviving myocardium after MI appears to result from dif-
ferent pathological processes resulting in unique structural quality,
ECM composition, and metabolic properties. Additionally, there is
also a time component to scar development that has to be con-
sidered. For example, reactive fibrosis in the setting of pressure
overload is initially characterized by perivascular fibrosis that later
progresses to interstitial fibrosis. Fibrosis is also highly dynamic
as it typically entails recruitment of fibroblasts and their conver-
sion into myofibroblasts, excessive synthesis and secretion of ECM
and ECM-associated modulatory glycoproteins, posttranslational
modification and cross-linking of ECM proteins, and dysregulation
of ECM production and breakdown by matrix metalloproteinases
(MMPs) and their endogenous inhibitors (TIMPs). These different
manifestations of fibrosis suggest that multiple targets or thera-
peutic opportunities may exist and that therapy may have to be
personalized according to the diagnosis of specific remodelling pro-
cesses and finally specific types of fibrosis.
Because todays’ ‘one size fits all’ guideline approaches and broad
heart failure patient classifications do not properly consider the ..
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.. different pathological processes that underlie fibrosis formation, it
may not be a surprise that the outcomes of various studies are
often contradictory and can only be rarely translated from one
clinical setting to another. Also, as a consequence, fibrosis has not
yet emerged as a primary target for heart failure therapies.
The Translational Research Committee of the Heart Failure
Association (HFA) of the European Society of Cardiology (ESC)
organized a workshop on myocardial fibrosis with the aim to
discuss and recommend strategies to address knowledge gaps in
this field. This scientific roadmap paper summarizes the principal
knowledge gaps that were identified, including the need for (i)
more specific definitions of processes underlying the formation of
fibrosis in heart failure under different pathological conditions, (ii)
improved methods to detect fibrosis using imaging techniques and
biomarkers associated with specific entities of fibrosis; and (iii) new
therapies to directly target specific processes underlying cardiac
fibrosis. Here, we provide a framework to better define fibrosis
during various stages, aetiologies, and severities of heart failure.
We propose a structured experimental scheme to assess fibrosis
quality as well as quantity, and to provide a work-up template that
can be used in both translational and clinical research. Our goal is to
direct future research to the identification of individual mechanisms
of fibrosis formation, anticipating that this will provide insight into
novel therapeutic targets and diagnostic tools for cardiac fibrosis
stratification during heart failure progression.
More specific definitions are
needed to describe the formation
of myocardial fibrosis in heart
failure
Myocardial fibrosis in heart failure is not
a uniformly initiated process
Myocardial fibrosis is an endogenous, albeit suboptimal, repair
response of the failing heart that can offer structural support
while cardiomyocyte loss is occurring in the absence of appro-
priate cardiomyocyte replacement. Several key events characterize
the fibrotic response to cardiac injury, which have been excellently
reviewed elsewhere.1–5 Activation and conversion of fibroblasts
into myofibroblasts are central events, critical also to non-cardiac
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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wound healing.1–5 Myofibroblasts produce and deposit ECM pro-
teins, such as collagens, glycoproteins and proteoglycans (e.g.
fibronectin, galectins, and periostin among many others), to offer
local mechanic support to the failing heart. The formation of
organized fibrotic structures and fibrils requires a multi-step pro-
cess that involves the degradation and processing of existing
ECM to remove damaged tissue, and the production, secretion,
cross-linking, and maturation of new ECM. In addition to cardiac
fibroblasts, which are the major source of ECM, monocytes and
macrophages home to sites of injury and contribute to remod-
elling by secretion of pro-fibrotic growth factors. Finally, cardiomy-
ocytes also contribute to secretion of pro-fibrotic growth factors
into the ECM via paracrine mechanisms. In addition to fibrillary
ECM constituents, non-structural glycoproteins and proteoglycans
are important accessory mediators of fibrosis. Glycosylation is a
highly prominent post-translational modification in ECM (reviewed
by Rienks et al.6) and glycoproteomics is a novel tool with promise
in the study of myocardial fibrosis.7,8
Timely detection of fibrosis and determination of its state could
potentially help to diagnose and stop heart failure progression early
on. Capturing where fibrosis lies along the time continuum in a
specific patient may inform physicians if fibrosis is developing as an
early manifestation of the disease, and what type of targeted ther-
apy could be employed. Early post-MI therapy will most certainly
differ from the therapy of non-ischaemic diastolic dysfunction with
a stiff left ventricle and even more from the treatment of end-stage
heart failure with an often severely fibrotic myocardium. The exact
differences in disease states, including the identification of disease
modulators, must be identified to improve and ideally establish an
individualized therapy of heart failure-related fibrosis.
Current classification of myocardial
fibrosis
Traditionally, the form and stage of fibrosis have been denoted
in line with the specific physiological phenomena that provoked
the fibrotic response. Classically, the fibrotic process occurring
after MI has been called ‘reparative’ or ‘replacement’ fibrosis.While
scar formation is characterized by excessive accumulation of ECM,
fibrosis is generally regarded as inevitable, as its absence would
extend ventricular dilatation and could even result in ventricular
rupture. Therefore, the infarct scar is a mandatory, albeit not per-
fect replacement, structural support. The post-MI scar is the result
of dramatic cardiomyocyte loss and the subsequent deposition
of collagen fibrils that are cross-linked to provide a strong ECM net-
work. Reactive fibrosis, which is typically observed as perivascular
or interstitial fibrosis, is stimulated by ongoing long-run maladaptive
signalling (e.g. by inflammatory cells, paracrine signals, and oxidative
stress) that is part of progressive pathological cardiac remodelling.
Figure 1 summarizes the different types of fibrosis which may all
be observed in parallel in the same heart, making it a challenging
exercise to target distinct fibrotic processes. It depicts an example
of histology from a virtual cardiac tissue biopsy — it becomes
instantly apparent that even within the tissue same sample, different
forms of fibrosis may be present, and thus, the chances for sampling
error in real life are very real. Some fibrotic manifestations will be ..
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.. ‘reactive’, some will have been ‘reparative’, some will be (or have
become) static, and others dynamic. It is quite often not feasible
to distinguish the various forms, as many features are shared and
transition into one another is possible. Thus, identification of the
specific and probably dominant type of fibrosis will be important
for individualized anti-fibrotic approaches.
Understanding myocardial fibrosis
in different phenotypes of heart
failure
Fibrosis is frequently described in experimental heart failure in pre-
clinical animal models. Given its complex pathophysiology, it is cru-
cial in such studies to provide a minimum amount of information
to allow the reader understanding what fibrosis is referred to. Fur-
ther, the triggers, dynamics, and characteristics of the fibrotic pro-
cess are very different among various aetiologies of heart failure.
Below, we discuss cardiac fibrosis in the setting of MI, pressure
overload, and aging (Figure 2), as well as genetic cardiomyopathies
and heart failure with preserved ejection fraction (HFpEF).
Myocardial fibrosis in post-myocardial
infarction
Myocardial infarction is one of the most common causes of heart
failure. Several animal models have been developed to model
human MI. Permanent ligation of a coronary artery induces a
large transmural MI (rat, mouse, dog, sheep, pig), while tran-
sient ligation causes ischaemia–reperfusion damage (mouse, rat,
dog, pig), with variable degrees of damage depending on dura-
tion of ischaemia, selection of coronary artery, location of the
ligature, and pre-treatment. MI causes a distinct tissue wound heal-
ing response with an initial strong inflammatory response, start-
ing immediately after MI and peaking 3–7 days (depending on the
species studied and model used) after MI. Neutrophils, mono-
cytes, macrophages, but also fibroblasts themselves release factors
that act on fibroblasts and trigger a pro-fibrotic response to form
the infarct scar. The controlled invasion of inflammatory cells is a
prerequisite for proper infarct healing and prevention of myocar-
dial rupture.9–13 After the initial phase, inflammation subsides and
the proliferative phase starts, where fibroblasts convert into myofi-
broblasts, migrate and proliferate, resulting in an increased capacity
for wound contraction and repair. Additionally, fibroblast progen-
itors as well as endothelial to mesenchymal transition are consid-
ered important post-MI fibroblast sources. Collagen content begins
to rise measurably 4–7 days after MI and peaks after 3–6weeks,
depending on the animal model used. Beside the amount of colla-
gen, the type of collagen fibres formed and the degree of collagen
cross-linking affect the mechanical properties of the tissue. Finally, a
maturation phase is reached, where a stable scar is formed. During
this phase, it is unclear whether the reduction in ECM turnover
is due to reduced matrix synthesis, increased ECM breakdown,
or both.
The precise role of fibroblasts and the fibroblast cell sources in
the post-MI setting is incompletely understood, in part because
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Different forms of fibrosis are not mutually exclusive. The left panels show replacement (upper panel), reactive interstitial (middle),
and perivascular (lower) fibrosis, with different cells playing the major role: fibroblasts (green), inflammatory cells (blue), and myocytes (red),
with fibrillar debris interpositioned. In reality, in a typical failing heart, all forms may occur (middle panel and right histology panels). (Illustration:
Maartje Kunen, Medical Visuals.)
of difficulties in labelling and identifying this cell type in vivo.
Recently, fibroblast activating protein (FAP) was identified as a
rather specific marker of activated, collagen-synthesizing fibrob-
lasts, whereas inactive fibroblasts, or fully differentiated myofibrob-
lasts and non-fibroblast cells in the infarct do not express FAP.11
Periostin is suggested as another marker of activated fibroblasts,
suggestive for early fibroblast activation.14 Isolating post-MI car-
diac fibroblasts from an in vivo-stimulated environment and evalu-
ating these cells ex vivo has provided insight into their functional
responses.12,13
Myocardial fibrosis in models of pressure
overload (e.g. hypertension)
The importance of fibrogenesis in pressure overload has been
reviewed by Creemers and Pinto.3 Excessive myocardial ECM
formation and collagen production take place in both human and
experimental heart failure resulting from pressure overload, and
collagen formation becomes disproportionate to left ventricular
mass when the stress becomes chronic and sustained.3 Transform-
ing growth factor (TGF)-𝛽 is a central protein in the formation ..
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.. of pressure overload-related fibrosis. It is activated by various
circulating hormones such angiotensin II and endothelin-1, but
also by cellular stretch and strain. The TGF-𝛽 pathway leads to
activation of Smad2/3 and Rho/ROCK signalling, and activation
of stress-related kinases and proteins such as p38, ERK1/2 and
elevated expression of connective tissue growth factor (CTGF).
Fibroblasts in models of pressure overload have been identified
as epicardial and endothelial cell-derived and Pax3-expressing cells
(a major source under normal conditions and following pressure
overload).15,16 Premature senescence of myofibroblasts was identi-
fied as an essential anti-fibrotic mechanism and potential therapeu-
tic target in myocardial fibrosis in response to pressure overload.17
Aging
Aging is one of the key drivers of myocardial fibrosis (reviewed
in18–25). Animal models and human biopsy studies have
demonstrated that collagen content of the heart progres-
sively increase with advanced age, and collagen deposition is
associated with increased wall stress, and with diastolic and
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Graphical depiction of time-dependent fibrosis formation in the heart after acute injury such as myocardial infarction, longstanding
injury such as hypertension, and intrinsic tissue changes during aging and senescence. The aetiological factors underpinning fibrosis, as
well as the (physiological) need for a fibrotic reparative response will dictate the extent and timing of the fibrotic process. (Illustration:
Maartje Kunen, Medical Visuals.) AngII, angiotensin II; CTGF, connective tissue growth factor; DAMPS, danger-associated molecular patterns;
ET-1, endothelin-1; IL, interleukin; L, lymphocyte; Ma, macrophage; MC, mast cell; MCP-1, monocyte chemoattractant protein-1; MF/MyoF,
myofibroblast; MMP, matrix metalloproteinase; MV, microvessel; N, neutrophil; PAI, plasminogen activator inhibitor; PDGF, platelet-derived
growth factor; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinase; TNF, tumour necrosis factor.
systolic ventricular dysfunction. With aging, not only the pro-
duction of collagen increases, but also the degradation becomes
less effective.18,20,21 Also collagen processing and maturation is
different, and cross-linking seems to increase.18,20,21 The triggers
for fibrosis in the aging heart are manifold, and, as a result, fibrosis
may present in multiple forms. In response to cardiomyocyte
injury and cell loss, replacement fibrosis may be seen. At the same
time, with ongoing inflammation and age-dependent increases in
oxidative stress, interstitial fibrosis may occur. We must realize
that age-dependent fibrosis will usually develop alongside, so in
concert with fibrosis that develops in response to cardiac injury,
which complicates the understanding of what causes and then
supports sustained fibrotic processes.
Myocardial fibrosis in (genetic)
cardiomyopathies
Fibrosis in (mono-) genetic cardiomyopathies can occur as fine
interstitial fibrosis or replacement fibrosis, both due to structural
changes in response to the gene defect. Therefore, the observa-
tion of fibrosis for instance on cardiac magnetic resonance imaging
(MRI) is generally regarded as an early sign of the disease, even ..
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. when systolic function is still normal.26,27 Early fibrosis in cardiomy-
opathies is regarded as a malicious event as the need for cardiac
repair usually is minimal. Clearly, the events triggering fibrosis in
cardiomyopathies are very heterogeneous, and encompass events
such as cell death, metabolic derangements, neurohormonal acti-
vation, and direct toxic effects of mutated proteins.28
Myocardial fibrosis in heart failure
with preserved ejection fraction
Heart failure with preserved ejection fraction accounts for almost
half of the cases of heart failure. Co-morbidities, including aging,
obesity, hypertension, and diabetes, are key factors for HFpEF pro-
gression into overt heart failure. Recent evidence suggests that
in HFpEF the extent of myocardial fibrosis (as measured by T1-MRI,
see below) is related to the degree of diastolic dysfunction.29,30
Clearly, pro-fibrotic signals are diverse and differ from classical,
systolic, heart failure signals. Fibrosis in HFpEF usually presents
as perivascular and fine interstitial fibrosis and is associated with
systemic inflammation.31 As a consequence, fibrosis in HFpEF will
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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likely be multifaceted, with fibrosis due to aging, due to hyperten-
sion, and in response to inflammatory and metabolic (obesity) trig-
gers, with occasional superimposed reparative fibrosis, in case of
(small) MI or myocarditis. Clearly, the current call to better pheno-
type HFpEF resonates particularly for the understanding of fibrosis
in this complex disease.31
The ‘chronic fibrotic response’ in heart
failure
From the discussion above it becomes clear that in heart failure
(and in fact in more chronic diseases), a sustained fibrotic response
is observed, that initially may be reparative, but at some point,
rather contributes to organ damage and failure. So, it seems that
in certain forms and stages of heart failure the fibrotic response
cannot be switched off, and that a certain degree of fibrogenesis
remains persistent. This is different from physiological healing,
where the termination of the reparative phase is identified by the
disappearance of activated myofibroblasts from the tissue.32,33
It is currently unknown how to differentiate the endogenous,
necessary and beneficial fibrotic response or matrix turnover from
the excessive, ongoing and harmful chronic fibrotic response that
leads to matrix deposition and tissue stiffening.34 We postulate
that these triggers that cause this chronic fibrotic response are
multifold, including sustained fibroblast proliferation via feedback
loops, cardiomyocyte-mediated fibroblast activation, inhibition of
myofibroblast apoptosis, and the presence of sustained low-grade
systemic and local inflammation.
Although mechanistically this remains largely a black box,
several players have been recognized. As described above,
TGF-𝛽 plays a central role in fibroblast proliferation and
fibroblast-to-myofibroblast conversion. TGF-𝛽 is produced in
high numbers by myofibroblasts to create a vicious cycle of
myofibroblast activation. TGF-𝛽 stimulates several growth factors
(epidermal growth factor, insulin-like growth factor-1, growth dif-
ferentiation factor-11), which mediate proliferation of fibroblasts,
involving autocrine signalling via fibroblast growth factor-2 and/or
CTGF.35,36 TGF-𝛽 also prevents myofibroblast apoptosis, via
stimulation of PI3K/AKT pro-survival signalling pathway.37 ‘Myofi-
broblast persistence’ may lead to non-resolving and progressive
fibrosis, as exemplified by human idiopathic pulmonary fibrosis.38
Experimental drugs targeting the TGF-𝛽 and MAPK pathways
indicate that the myofibroblast phenotype can be reversed, but
whether this also can be achieved in vivo remains unclear.39,40
The low-grade, persistent systemic inflammation that is
observed in heart failure41–44 is a major driver of fibrosis.
TGF-𝛽 has pleiotropic effects on the immune system and has both
immunosuppressive and pro-inflammatory functions,44 and may
polarize macrophages and neutrophils towards a M2 phenotype,
which produces large quantities of inflammatory cytokines.
Experimental studies suggest that regulating the inflammatory
and immunomodulatory response may be effective in reducing
MI-related remodelling, fibrosis and outcomes. For example, in
a recent mouse study, neuregulin-1, an epidermal growth factor
family member released by cardiac endothelial cells, attenuated
myocardial interstitial fibrosis by inhibiting activation of myocardial ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. macrophages.45 Most compelling evidence form the preclinical field
was generated for tumour necrosis factor (TNF)-𝛼 inhibition43,46
but surprisingly, clinical studies e.g. with steroids and TNF-𝛼 block-
ers showed no or even detrimental effects, so that initial translation
of experimental observations to clinical medicine has failed,44 sug-
gesting that broad targeting of the immune system will not be
a useful therapeutic strategy. Of interest, the recent CANTOS
trial showed that targeted inhibition of inteleukin-1𝛼 did reduce
cardiovascular (and cancer) outcomes, albeit to a small degree.47
Proposal for a minimum assessment
profile to screen cardiac fibrosis
The term ‘myocardial fibrosis’ needs to be specified with more pre-
cision and potentially individualized to offer effective therapeutics
to patients with heart failure and cardiac fibrosis. For experimental
studies, we propose a minimum set of parameters that should be
provided to allow readers to appreciate the nuances of the fibrosis
phenotype present. These items are listed in Table 1. In Table 2, we
summarize the key functions, disease conditions, analytical meth-
ods and biomarkers in different forms of fibrosis. These insights are
crucial to identify therapeutic opportunities for various subtypes of
fibrosis-induced heart failure.
Improved methods are needed
to detect fibrosis using
biomarkers and imaging
techniques
Detection of myocardial fibrosis is not straightforward in animal mod-
els and is even less so in the clinical setting where myocardial tissue
sampling is not readily available. The gold standard for human studies is
to assess the quality (i.e. focal, interstitial or perivascular distribution)
and to quantify fibrosis in myocardial tissue biopsies using histolog-
ical techniques (i.e. Masson’s Trichrome or Sirius Red histochemical
staining). Although endomyocardial biopsies (EMBs) are limited by sam-
pling error and small tissue fragments, the study of explanted hearts
for heart transplantation offers unique possibilities with regard to spa-
tiotemporal histological analyses and modern -omics techniques, not
hampered by lack of tissue. We aware of several (national) initiatives,
where all explanted hearts will be archived centrally to ensure proper
sample size (so-called heart banks), and we foresee these will gener-
ate valuable information on fibrosis as well. But to date, tissue studies
are mostly still carried out on EMBs, requiring an invasive proce-
dure with the associated risk for complications and sampling errors.48
Thus, alternative, non-invasive and ideally equally or even more reliable
methods should be developed and broadly applied.
Circulating biomarkers of myocardial
fibrosis
Extracellular matrix proteins or cleaved processing products are
often released into the systemic circulation and therefore measurable
in serum or plasma using reliable and approved methods (e.g. ELISAs).
Commonly used fibrosis biomarkers give insight into collagen produc-
tion [e.g. procollagen type I N-terminal propeptide, procollagen type
III N-terminal propeptide (PIIINP)] or the secretion of non-structural
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Proposed minimal dataset to describe fibrosis in animal studies
Parameter Example(s)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Species Mouse, rat, sheep, pig
Precise reporting of strain, genetic background, age
Perturbation Pressure overload, MI by permanent LAD ligation or ischaemia/reperfusion injury, diet, salt
loading
Precise reporting of duration of intervention and period of ischaemia and pressure overload
Time course Reporting the time course of disease progression, with samples taken before and at several time
points [acute, subacute (days) and chronic (months)] post-disease induction
Assessments
Histology For instance: Masson, Picrosirius red
Percentage of LV tissue affected, sampled ROIs;
Use of validated antibodies for immune histology
• Reparative (scarring) fibrosis vs. reactive fibrosis (quantitative or semiquantitative)
• Amount of fibrosis (quantification), perivascular, interstitial, scarring
• Quality: thickness and % collagen cross-linking (Sirius red polarization, specific antibodies)
• Myofibroblast staining (smooth muscle cell actin staining)
• Electron microscopy for collagen fibre morphology
Inflammation glycoproteins-proteoglycans in
the heart at RNA and protein level
- Acute vs. chronic process (duration of disease)?
Glycoproteins/proteoglycans:
• Periostin
• Osteopontin
• Syndecans
• Thrombospondins
• Osteoglycin
• TGF-𝛽
• CTGF
• Galectin-3
• Interleukin 1, -10, -11
• Others pending on cardiac disease
- Quantification of inflammation (myeloperoxidase, CD45- and CD68-staining leucocytes).
- Collagen crosslinking enzymes (LOX’s)
- MMP/TIMPs at transcript level and zymography
Blood biomarkers Galectin-3
CITP
PIIINP
ST2
Imaging MRI (T1 mapping, late enhancement fibrosis)
Functional analyses Echocardiography and invasive haemodynamics for determining load-dependent diastolic and
systolic function
CITP, C-terminal propeptide of procollagen type I; CTGF, connective tissue growth factor; LAD, left anterior descending artery; LOX, lysyl oxidase; LV, left ventricular; MI,
myocardial infarction; MMP, matrix metalloproteinase; MRI, magnetic resonance imaging; PIIINP, procollagen type III N-terminal propeptide; ROI, region of interest; TGF,
transforming growth factor; TIMP, tissue inhibitor of metalloproteinases.
(glyco)proteins that modulate the collagen production itself or its mat-
uration (e.g. periostin, mimecan, monocyte chemoattractant protein-1,
or galectin-3). In addition, several MMPs (e.g. MMP-3, MMP-9, MMP-11,
and MMP-12) and their tissue inhibitors (e.g. TIMP-1 and TIMP-3)
involved in the balance of collagen degradation, are released into
the blood stream and can be measured reliably. In fact, there is a
wide body of literature on the potential utility of these markers alone
or in concert.49 In general, many of these markers are valuable for
clinical risk prediction. Interestingly, several factors have been shown
to predict the response to treatment with anti-fibrotic properties,
such as mineralocorticoid receptor antagonists.50 However, the use
of these markers has not become a clinical standard because of limited
power in fully adjusted models with clinical variables, and because of ..
..
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..
..
..
..
..
..
..
..
..
..
.. technical difficulties in measuring the proteins, often requiring labori-
ous and expensive radioimmunoassays. Recently, several new emerg-
ing fibrotic markers have been studied, including galectin-3, sST2, and
periostin.51 These markers can generally be measured with Food and
Drug Administration-cleared ELISA assays which allow fast turnaround
times.
Circulating levels of fibrosis markers may not parallel findings in his-
tologically proven cardiac fibrosis and therefore caution is required in
the interpretation of systemic venous circulating biomarker levels in
relation to myocardial disease. López et al.52 measured circulating levels
of many fibrotic markers and correlated these in the same patients
to local cardiac tissue fibrosis volumes measured with histology. The
results show that out of 28 potential biomarkers associated with
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Systemic biomarkers, measured in the plasma of patients with heart failure, ideally reflect changes in the heart muscle. For
cardio-specific biomarkers, such as natriuretic peptides and troponins, this is very accurate. However, for many (more novel) markers that are
expressed by many organs outside the heart as well, the systemic levels only marginally reflects cardiac production. BNP, B-type natriuretic
peptide. (Illustration: Maartje Kunen, Medical Visuals.)
build-up or breakdown of myocardial fibrosis, only C-terminal propep-
tide of procollagen type I (CITP) and PIIINP correlated with histolog-
ical findings. This may be explained because in heart failure patients,
several other organs undergo fibrotic changes as well: liver, lungs, kid-
neys, and vessels. A recent article by Du and colleagues showed that
galectin-3, growth differentiation factor-15, and TIMP-1 plasma levels
do not reflect myocardial fibrosis in mouse models of post-MI heart
failure, hypertensive heart failure, and HFpEF.53 Instead, production
in extracardiac tissues such as fatty and lung tissue had much greater
impact on plasma levels of these markers. So ideally, we would need
a marker that is specific for cardiac fibrosis, or at the very least, ade-
quately reflects changes in myocardial fibrosis. However, since most
fibrotic pathways are shared amongst organs, such a marker may not
exist and it is therefore simply impossible to use circulating fibrosis
markers as a perfect surrogate for myocardial fibrosis (Figure 3). Fur-
ther, the markers generally do no clearly distinguish between various
forms of fibrosis, or between the trigger that causes fibrosis. There-
fore, the use of these factors for precision diagnostics is questionable,
but excess local production however may be used to target specific
treatment. Further, the potential of fibrotic markers as surrogate out-
comes in phase I/II trials is likely to be limited at this point, in view of
the limited specificity of available fibrotic (bio-)markers.
Imaging techniques to visualize
and quantify fibrosis
The most widely applied imaging technique in contemporary heart
failure management is echocardiography. Classical two-dimensional
echocardiography, however, provides little information about the pres-
ence or extent of fibrosis. More modern techniques such as tissue ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
. velocity imaging and global longitudinal systolic strain provide mechan-
ical tissue details that associate with myocardial fibrosis by biopsy
examination.54–56 In addition to echocardiography, cardiac MRI is a
technique that is replacing EMB as gold standard for human cardiac
fibrosis identification and quantification. Clearly, the use of cardiac MRI
cannot fully replace echocardiography as first-choice imaging modal-
ity, given the high costs. But in order to perform in deep pheno-
typing, with the aim to choose patients with specific pathophysio-
logical characteristics, or to monitor these during (drug) treatment,
cardiac MRI has distinct benefits. Using delayed gadolinium enhance-
ment, it is possible to visualize scar tissue, for instance after trans-
mural myocardial infarction. While delayed gadolinium enhancement
mainly identifies focal reparative fibrosis, modern techniques in cardiac
MRI are developing that may be able to provide more granularity in
imaging fibrosis. Most interestingly, T1 mapping is such an emerging
cardiac MRI technique, measuring the longitudinal relaxation time of
individual protons, which is depicted as a pixelated map. T1 mapping
allows the quantification of extracellular volume (ECV) fraction of the
myocardium. ECV is not a pure measure of fibrosis, although it has
been evaluated to this aim,57,58 but ECV rather mirrors diffuse changes
including fibrosis, but also interstitial oedema, protein degradation and
aggregation, lipid accumulation, and deposition of iron or amyloid. A
recent HFA position paper discusses in detail the (fast) developments
in imaging techniques.59 Furthermore, the presence and the extent
of MRI-proven fibrosis have been related to poor clinical outcomes.5
Collectively, different imaging (MRI) techniques may be applied as sur-
rogate measures for the presence and extent of myocardial fibrosis.
The next challenge is to develop a therapeutic plan to reverse or pre-
vent further development of fibrosis based on the cardiac magnetic
resonance findings. A promising approach would be to label specific
molecules with established relation to myocardial fibrosis, and image
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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those, e.g. by nuclear techniques, with the ultimate aim to target this
specifically.60
New therapies are needed
to directly target myocardial
fibrosis with specific drugs
It has been proposed for several years that direct targeting fibro-
sis might be useful in heart failure.1,61,62 Angiotensin-converting
enzyme inhibitors and mineralocorticoid receptor antagonists
reduce fibrosis formation, but clearly a residual fibrotic burden
remains and with that, a potential need to target it in order to
improve outcomes. It is crucial to ascertain where the fibrotic pro-
cess is, at a given time point, what the triggers are, and which cells
and proteoglycans play a role. The complexity of targeting fibrosis
is illustrated by a recent article by Clarke and colleagues,62 pro-
viding an example for why MMP inhibition may not be as effective
as previously hypothesized. They postulate that early during the
remodelling phase, MMP inhibition might be less effective because
there is little collagen to degrade, while at later fibrotic phases
it is less effective because MMP levels have fallen to low levels.
Therefore, the setting, the aetiology and the timing, all appear very
important in MMP inhibition and this could in part explain the dis-
appointing results thus far. Next, we will discuss a few novel options
that are on the horizon.
Connective tissue growth factor
and pirfenidone
Inhibition of fibrosis formation in pressure overloaded heart is best
achieved by alleviating the primary stressor,3 i.e. the elevated pres-
sure. TGF-𝛽 (e.g. pirfenidone), angiotensin or endothelin receptor
blockers, ERK inhibitors or inhibition of CTGF are being tested
as specifically fibrosis targeted treatments. Different from post-MI
fibrosis, it appears that inhibition of the excess fibrosis in pressure
overload is generally safe and well-tolerated.
Connective tissue growth factor (or CCN2) is a matricellular
protein and modulates the signalling of many cytokines and ECM
signals including those of TGF-𝛽, bone morphogenetic protein,
Wnt, vascular endothelial growth factor, and integrins. Because
it modulates multiple pathways simultaneously, and via several
different mechanisms, the effects of CTGF are combinatorial
and context-dependent (i.e. dependent on the environment and
mediators present), and therefore, the biology of CTGF is very
complex.63 CTGF expression is induced by many different patho-
physiological insults, and when it becomes overexpressed, it helps
promote differentiation of cells to become activated myofibrob-
lasts that deposit and remodel the ECM. CTGF is involved in
multiple positive feedback loops that can propagate tissue remod-
elling and fibrosis, and therefore it should be considered a central
mediator of fibrosis. Consequently, the goal of inhibiting CTGF is
to disrupt these positive feedback loops and arrest the progres-
sive nature of fibrosis (and possibly reverse it). A human mono-
clonal antibody, FG-3019, that binds to CTGF and interferes with ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. its activity has proven beneficial in rodent models of MI (unpub-
lished), neonatal (rat) bronchopulmonary dysplasia,64 and thoracic
aorta constriction model.65 Clinical testing of FG-3019 indicates an
excellent safety profile and has been tested in approximately 400
patients with diabetic kidney disease, pancreatic cancer, idiopathic
pulmonary fibrosis, or liver fibrosis.
Pirfenidone is a synthetic molecule that has been reported
to decrease the expression of various pro-fibrotic factors,
including TGF-𝛽1, TNF-𝛼, platelet derived growth factor and
collagen.66 Results from experimental models provided evidence
for a therapeutic utility of pirfenidone in pressure overload67–69
and hypertension,68 leading to a reduction in arrhythmogenic
substrate.70
Matrix metalloproteinases
The effects of regulating MMP activity on cardiac fibrosis
and left ventricular remodelling outcomes have primarily been
assessed in MI models. Targeted deletion and transgenic mice or
MMP inhibitors (MMPi) reveal both beneficial and detrimental
consequences.71 While early promises of MMPi in animal models
were encouraging, these findings have not translated to humans.
This has been due to selectivity and specificity issues, as well as
our lack of understanding of the full range of MMP functions.71 For
example, the MMP-9 substrate list includes hundreds of substrates
ranging from collagen and fibronectin, interleukin-1𝛽, pro-enzymes
and citrate synthase.72,73 Further, not all MMPi have been beneficial,
as MMP-12i given at 3 h post-MI suppressed neutrophil apoptosis
to prolong inflammation, resulting in exacerbated left ventricular
dilatation.74 MMP-28 deletion inhibited M2 anti-inflammatory
macrophage activation to stimulate left ventricular dysfunction
and increase cardiac rupture rates.75 If anything, these results
indicate how complex the fibrotic process in heart failure is, and
the specific role of MMPs herein. There is a need, therefore, to
delineate individual MMP roles under specific conditions and times.
Galectin-3 inhibitors
Galectin-3 is a lectin binding galactoside, and has been shown
to be upregulated in heart failure by myofibroblasts, mono-
cytes and macrophages that are recruited towards sites of injury
and fibrosis.76,77 Studies in mice deficient for galectin-3 have sug-
gested that galectin-3 is not a bystander but rather a culprit for
myocardial fibrosis.78,79 Inhibition of galectin-3, either achieved with
large carbohydrates,78,79 or antisense RNA,80 or small designer
molecules,81 effectively reduces organ fibrosis.82
Non-coding RNAs
Recently, non-coding RNA (both microRNA and long non-coding
RNAs-based)-based treatment strategies for fibrosis have been
put forward.83,84 Specific non-coding RNAs seem to play crucial
roles in the regulation of the cardiac fibroblast phenotype and
their modulation seem to be effective both in animal as well
as clinical studies; indeed there is currently a phase II trial in
patients with kidney fibrosis using an inhibitor of microRNA-21
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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(http://regulusrx.com/programs/pipeline/). Thus, non-coding
RNA-based treatment approaches might provide an opportunity
also for the treatment of cardiac fibrosis and remodelling, if
those microRNA inhibitors could be selectively delivered in the
heart — miRNA-21 is ubiquitously expressed. Other microRNAs,
such as miRNA-29b, appear to have a more cardio-specific effect.85
Future directions and conclusions
In this article we discuss several challenges and requirements in the
study of fibrosis (Table 3). For future applications, strategies that
allow for differentiation of fibrosis subtype are needed. Preclinical
studies in relevant animal models to better understand the dynam-
ics of fibrosis formation, degradation, and their importance for
the functional phenotype are therefore required. More advanced
in vitro models might allow a better functional control and mech-
anistic understanding. Whereas further optimizations are needed
to implement human cardiac disease parameters,86 these well con-
trolled environments allow longitudinal evaluations and screening
of anti-fibrotic strategies. Accumulating data linking fibrosis to a
stronger inflammatory response are at the initial phases. At later
time points, fibrosis-specific mediators and pathways (predomi-
nantly fibroblast-specific factors such as TGF-𝛽, osteopontin, and
galectins) contribute to the progression of fibrosis, and are dis-
tinct from the mechanisms driving inflammation. The presence of
co-morbidities should be considered — e.g. it has recently been
discussed that co-morbidities such as cancer may obscure the
biomarkers’ signals.87 Thus, to design effective therapeutics for
fibrotic disease, inflammation triggering fibrosis is to be consid-
ered, and the challenge ahead is to target specific molecules and
pathways that act on fibrosis (specific interleukins) while leav-
ing the (often beneficial) effects of the inflammatory response
uninhibited. A vast diversity of inflammatory, immunological, and
molecular mechanisms collectively contribute to cardiac fibrosis:
the complex interplay between adaptive immune system activation,
fibroblasts-to-myofibroblast conversion and proliferation, mast cell
activation, neutrophil influx, and production, modulation, matura-
tion and apposition of collagens, the embedding in the extracellular
milieu. These should all be considered and taken into account dur-
ing the design and testing of new anti-fibrotic therapies.
Clinically, disease-specific (bio-)markers and imaging modali-
ties — acting as surrogate parameters of specific temporal stages
of fibrosis — will help to identify patients who might benefit from
a specific therapy. Until recently, attempts to inhibit fibrosis have
been mostly focusing on single pro-fibrotic factors. Since fibrosis
is driven and sustained by the activation of multiple interconnect-
ing and intercommunicating pro-fibrotic pathways, a multi-target
approach will likely help to slow down the progression of fibrosis.
Using systems biology approaches and multi-omics technologies to
understand network signalling will aid in these efforts. Ultimately,
a concerted anti-fibrotic strategy that collectively targets impor-
tant inflammatory signalling molecules, pro-fibrotic cytokines, and
cellular functions should be considered in developing therapies to
adequately treat fibrosis.
In conclusion, in this position paper we have summarized the cur-
rent knowledge gaps in the myocardial fibrosis field and provided ..
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.. Table 3 Key recommendations
Challenges Requirements
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Improvement and
refinement in
describing fibrosis
1 Describe species, genetic background,
perturbation, background therapies
2 Describe disease and time point where
analyses were done
3 Describe quantity and quality of fibrosis
4 Describe culprit cells and associated
(glyco-) proteins
Improvement in
detecting fibrosis
1 Need for better imaging tools
2 Need for cardio-specific biomarkers
with relation to myocardial fibrosis
3 Improvement in -omics to better
pinpoint key factors that drive fibrosis
Targeting fibrosis 1 Gain precise awareness of what element
at what time point may be targeted
2 Novel (designer) drugs affecting
deleterious fibrosis
templates for assessing fibrosis in both translational and clinical
studies.
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